Logo
x

Search

Subscribe Now

astrazeneca

AstraZeneca’s Tagrisso (Osimertinib) Secures the EC’s Approval to Treat Unresectable EGFR-Mutated Lung Cancer

AstraZeneca’s Tagrisso (Osimertinib) Secures the EC’s Approval to Treat Unresectable EGFR-Mutated Lung Cancer

  • December 23, 2024
AstraZeneca and Merck Report P-III (OlympiA) Study of Lynparza to Treat Early Breast Cancer

AstraZeneca and Merck Report P-III (OlympiA) Study of Lynparza to Treat Early Breast Cancer

  • December 12, 2024
AstraZeneca to Feature Data from P-III (AMPLIFY) Study of Calquence Plus Venetoclax to Treat Chronic Lymphocytic Leukaemia at ASH 2024

AstraZeneca to Feature Data from P-III (AMPLIFY) Study of Calquence Plus Venetoclax to Treat Chronic Lymphocytic Leukaemia at ASH...

  • December 9, 2024
AstraZeneca Reports the US FDA’s sBLA Acceptance and Priority Review of Imfinzi to Treat Muscle-Invasive Bladder Cancer

AstraZeneca Reports the US FDA’s sBLA Acceptance and Priority Review of Imfinzi to Treat Muscle-Invasive Bladder Cancer

  • December 6, 2024
AstraZeneca’s Imfinzi (Durvalumab) Secures the US FDA’s Approval for Treating Limited-Stage Small Cell Lung Cancer

AstraZeneca’s Imfinzi (Durvalumab) Secures the US FDA’s Approval for Treating Limited-Stage Small Cell Lung Cancer

  • December 5, 2024
AstraZeneca Provides Update on P-III (CAPItello-281) Study of Truqap Regimen in PTEN-Deficient mHSPC

AstraZeneca Provides Update on P-III (CAPItello-281) Study of Truqap Regimen in PTEN-Deficient mHSPC

  • November 25, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.